The U.S. Food and Drug Administration has approved label expansions for Sanofi's Dupixent, extending its use to rare autoimmune conditions such as bullous pemphigoid, and Incyte's Monjuvi, widening its therapeutic scope. Concurrently, Novartis has introduced Mariana Oncology, adding to its oncology portfolio. These regulatory approvals reflect ongoing advancements in targeting immune-mediated pathologies and hematologic cancers, marking significant clinical progress and positioning these therapies for broader patient benefits.